Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.

Abstract

The polycomb repressive complex 2 (PRC2) can methylate at lysine 27 of histone H3 at the trimethylation level (H3K27me3). This leads to gene silencing and is known to be dysregulated in many cancers. PRC2 is made up of three core subunits: EZH2, SUZ12, and EED. EED is essential for the regulation of PRC2 function by the binding to H3K27me3. Targeting the allosteric site within EED offers new strategies to disrupt the PRC2 activity. In this mini review, we summarize some of the recent developments in small molecules that target EED and its interaction with other core proteins in the PRC2 complex.